Browse > Article

Phase II Study of Gemcitabine and Vinorelbine as a Combination Chemotherapy for the Second-Line Treatment of Nonsmall Cell Lung Carcinoma  

Lee, EunJoo (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Ha, EunSil (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Park, SangHoon (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Hur, GyuYoung (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Jung, KiHwan (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Jeong, HyeCheol (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Lee, SungYong (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Kim, JeHyeong (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Lee, SangYeub (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Sin, Chol (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Shim, JaeJeong (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
In, KwangHo (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Kang, KyungHo (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Yoo, SeHwa (Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, College of Medicine, Korea University)
Publication Information
Tuberculosis and Respiratory Diseases / v.59, no.5, 2005 , pp. 510-516 More about this Journal
Abstract
Backgroud : Lung cancer is the leading cause of cancer deaths in Korea and the number of lung cancer deaths is increasing. The higher response rates, decreased toxicity and improved performance status of the first-line treatments have resulted in an increased number of patients becoming candidates for second-line therapy. Several new antineoplastic agents, including gemcitabine, docetaxel and paclitaxel, have recently demonstrated second-line activity. This phase II study evaluated the efficacy and toxicity of gemcitabine and vinorelbine as combination chemotherapy for Korean patients with NSCLC as a second-line treatment. Methods : Sixty response-evaluable patients were enrolled from December 2000 to July 2003. We conducted a phase II study of a combination gemcitabine and vinorelbine chemotherapy for patients with histologically confirmed NSCLC that was stage IIIB and IV disease at the time of diagnosis, and the disease had progressed onward or the patients had relapsed after first-line platinum-based chemotherapy. They were treated with intravenous gemcitabine $1000mg/m^2$ and intravenous vinorelbine $25mg/m^2$ on days 1 and 8. This chemotherapy regimen was repeated every 3 weeks. Results : A total of 215 cycles of treatment were given and the mean number of cycles was 3.6 cycles. All the patients were evaluable for the toxicity profile. The response rate was 10% according to the WHO criteria. The median progression free survival was 3.8 months and the median survival time was 10.1 months. The 1-year survival rate was 32.9%. Grade III and IV neutropenia were seen in 20 (33.3%) and 7 (11.7%) patients, respectively. Conclusion : The combination of gemcitabine and vinorelbine is active and well tolerated as a second-line therapy for patients with advanced nonsmall cell lung carcinoma.
Keywords
Nonsmall cell lung cancer; Gemcitabine; Vinorelbine; Phase II study;
Citations & Related Records

Times Cited By SCOPUS : 0
연도 인용수 순위
  • Reference
1 Ardizzoni A, Tiseo M. Second-line chemotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). J Chemother 2004;16:104-7   DOI
2 Laack E, Mende T, Benk J, Cheaissani A, Scholtze J, Lorenz C, et al. Gemcitabine and vinorelbine as first-line therapy for non-small cell lung cancer: a phase II trial. Eur J Cancer 2001;37:583-90   DOI   ScienceOn
3 Shepherd FA. Phase II trials of single-agent activity of gemcitabine in patients with advanced non-small cell lung cancer: an overview. Anticancer Drugs 1995; 6:19-25
4 Jang PS, Kang HM, Lee JE, Kwon SJ, An JY, Lee YS, et al. Gemcitabine plus vinorelbine as second-line chemotherapy of the patients of previously treated non-small cell lung cancer. Tuberc Respir Dis 2005; 58:344-51   DOI
5 Park YH, Lee JC, Kim CH, Ryoo BY, Kim HT. Gemcitabine and vinorelbine as second-line therapy for nonsmall cell lung cancer after treatment with paclitaxel plus platinum. Jpn J Clin Oncol 2004;34:245-9   DOI   ScienceOn
6 Johnson SA, Harper P, Hortobagyi GN, Pouillart P. Vinorebine: an overview. Cancer Treat Rev 1996;22: 127-42   DOI   ScienceOn
7 Kim DH, Seo JW, Jung CS. The result of cause of death in 2003. Korea National Statistical office; 2004
8 Depierre A, Lemarie E, Dabouis G, Garnier G, Jacoulet P, Dalphin JC. A phase II study of vinorelbine in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991;14:115-9   DOI   ScienceOn
9 Herbst RS, Khuri FR, Lu C, Liu DD, Fossella FV, Glisson BS, et al. The novel and effective nonplatinum, nontaxane combination of gemcitabine and vinorelbine in advanced nonsmall cell lung carcinoma. Cancer 2002;95:340-53   DOI   PUBMED   ScienceOn
10 Comis RL. The current situation: erlotinib and gefitinib in non-small cell lung cancer. Oncologist 2005; 10:467-70   DOI   PUBMED   ScienceOn
11 Gridelli C, Perrone F, Gallo C, de Marinis F, Ianniello G, Cigolari S, et al. Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer: a two stage phage II study. Eur J Cancer 1997;33:392-7   DOI   ScienceOn
12 Kosmidis P. Interim results of a Phase III trial. Paclitaxel/carboplatin vs paclitaxel/gemcitabine in advanced non-small cell lung cancer. Oncology 2000;14:41-8
13 Sander AB, Nemunaitis J, Denham C, von Pauel J, Cormier Y, Gatzemeier U, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic nonsmall cell lung cancer. J Clin Oncol 2000;18:122-30   DOI
14 Abratt RP, Bezwoda WR, Falkson G, Goedhals L, Hacking D, Rugg TA. Efficacy and safety profile of gemcitabine in non-small cell lung cancer: a phase II study. J Clin Oncol 1994;12:1535-40   DOI
15 Pectasides D, Kalofonos HP, Samantas E, Nicolaides C, Papacostas P, Onyenadum A, et al. An out-patient second-line chemotherapy with gemcitabine and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy: a phase II study of the Hellenic co-operative oncology group. Anticancer Res 2001;21:3005-10
16 Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8   DOI   ScienceOn
17 Crino L, Scagliotti G, Marangolo M, Figoli F, Clerici M, de Marinis F, et al. Cisplatin-gemcitabine combination in advanced non-small cell lung cance: a phase II study. J Clin Oncol 1997;15:297-303   DOI
18 Hainsworth JD, Burris HA 3rd, Litchy S, Erland JB, Hon JK, Brierre JE, et al. Gemcitabine and vinorelbine in the second-line treatment of non-small cell lung carcinomas patients. Cancer 2000;88:1353-8   DOI   PUBMED   ScienceOn
19 Furuse K, Kubota K, Kawahara M, Ogawara M, Kinuwaki E, Motomiya M, et al. A phase II study of vinorelbine, a new derivative of vinca alkaloid, for previously untrated advanced non-small cell lung cancer. Lung Cancer 1994;11:385-91   DOI   ScienceOn
20 Georgoulias V, Scagliotti G, Miller V, Eckardt J, Douillard JY, Manegold C. Challenging the platinum combinations: docetaxel combined with gemcitabine or vinorelbine in non-small cell lung caner. Semin Oncol 2001;28:15-21   DOI
21 Georgoulias V, Samonis G, Papadakis E, Alexopoulos A, Tsiafaki X, Rapti A, et al. Comparision of docetaxel/cisplatin to docetaxel/gemcitabine as first-line treatment of advanced non-small cell lung cancer: early results of a randomized trial. Lung cancer 2001;34:S47-51   DOI   ScienceOn
22 Hanna NH. Second-line chemotherapy for non-smallcell lung cancer: recent data with pemetrexed. Clin Lung Cancer 2004;5:S75-9   DOI   ScienceOn
23 Bonomi PD. Therapeutic advances in second-line treatment of advanced non-small-cell lung cancer. Clin Lung Cancer 2004;6:154-61   DOI   PUBMED   ScienceOn
24 Carrato A, Rosell R, Camps C, Anton A, Garcia-Gomez R, Aranda E, et al. Modified weekly regimen with vinorelbine as a single agent in unresectable nonsmall cell lung cancer. Lung Cancer 1997;17:261-9   DOI   ScienceOn
25 Camps C, Martinez EN, Jaime AB. Second-line treatment with gemcitabine and vinorelbine in non-small cell lung cancer (NSCLC) cisplatin failures: a pilot study. Lung Cancer 2000;27:47-53   DOI   ScienceOn
26 Kosmas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, et al. Gemcitabine and vinorelbine as second-line therapy in non-small cell lung cancer after prior treatment with $taxene^{+}$platinum-based regimens. Eur J Cancer 2001;37:972-8   DOI   ScienceOn